Abnormal deposition of protein tau takes place in the brain of patients with several neurodegenerative diseases. Few of these patients present frontotemporal dementia with parkinsonism and amyotrophy , an autosomal dominant tauopathy related to mutations of the gene that codes for protein tau, localized in chromosome 17. The great majority of patients with tauopathies such as Alzheimer's disease, sporadic frontotemporal dementia or progressive supranuclear palsy do not show a Mendelian pattern of inheritance. We have occasionally seen tauopathies in patients with parkin mutations and, therefore, hypothesized that the protein tau interacts with parkin. We have tested that hypothesis in mice with combined genetic modifications of tau (over-expression of human tau with three mutations known to produce FTDPA-17) and parkin (deleted) proteins. Homozygote parkin null or over-expressing mutated-human tau mice have subtle behavioral and molecular abnormalities but do not express a clinical phenotype of neurodegenerative disease. Mice with combined homozygous mutations of these two genes show progressively abnormal walking already noticeable at 3 months of age, loss of dopamine and dopamine markers in striatum, nuclear tau immunoreactive deposits in motor neurons of the spinal cord, abnormal expression of glial markers and enhanced levels of pro-apoptotic proteins; findings that were absent or less pronounced in homozygote animals with deletions of parkin or over-expression of tau. The double transgenic mice do not express normal mechanisms of adaptation to stress such as increased levels of GSH and Hsp-70. In addition, they have reduced levels of CHIP -Hsc70, a complex known to attenuate aggregation of tau and to enhance ubiquitination of phosphorylated tau. We have found high levels of phosphorylated tau in parkin 2/2 1tau VLW mice and a relative decrease of the inactivated pSer9 to total GSK-3 levels. Our data reveal that there are interactions between tau and parkin that could be relevant for the pathogenesis and treatment of tauopathies. Similarly, we hope that the double transgenic parkin 2/2 1tau VLW mice could be useful for testing of compounds with putative therapeutic value in human tauopathies.
INTRODUCTION
Tau is a protein that stabilizes microtubules and plays a critical role in the neuronal transport system (1 -3) . Abnormal tau function and pathological deposits of this protein in the human brain have been described in a number of sporadic and familial neurological diseases, that produce different clinical phenotypes (4 -7). Alzheimer's disease is a mostly sporadic disorder with abnormal deposition of highly phosphorylated tau into the neurons. Frontotemporal dementias include a complex of # The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org different tauopathies, some sporadic, some familial, mostly related to different mutations of the tau gene, characterized by dementia with prominent deficits of the frontal lobe, such as apathy, disinhibition, change of personality, and often by parkinsonism (7) . Progressive supranuclear palsy (PSP) and cortico basal degeneration are mostly sporadic tauopathies (7) . Familial tauopathies, described in more than 100 families around the world, are clinically characterized by a variable combination of parkinsonism and dementia with prominent involvement of the frontal lobes, and are related to 34 known different mutations of the Tau gene, located in chromosome 17 (8 -10) . Most tauopathies, however, are of unknown origin and pathogenesis, and they are considered related to post-translational alteration of tau.
Tau interacts with many proteins in the brain. The best known interactions are those of tau and tubulin in the microtubules. In vitro experiments have revealed tau-mediated fibrillization of alpha-synuclein protein at low concentrations (11) , but accumulations of tau and amyloid beta-protein occur independently in the human entorhinal cortex (12) . Fe65, one of the ligands of the amyloid precursor protein (APP) cytodomain, is associated with tau in vivo and in vitro (13) . Great interest has been developed in the proteins that play a role in the phosphorylation of tau. Glycogen synthase kinase-3 (GSK-3) is one of them. Its function could be inhibited by compounds presently used in the clinic, such as lithium (14, 15) , or in the process of development. In addition, other proteins, such as the 14-3-3 protein, mediate the phosphorylation of protein tau by serum-and glucocorticoid-induced protein kinase 1 (16) .
The interrelations between tau and parkin are of particular interest. Van de Warremburg et al. (17) reported a family with parkin mutations and tau pathology in brain. Morales et al. (18) described a patient with autosomal recessive parkinsonism because of a single heterozygous C212Y parkin mutation, who had a clinical and pathological phenotype of PSP. That patient had tau pathology and high levels of phosphorylated tau in his brain (19) . As he had the high-risk genotype H1/H1 for development of tauopathies, it was concluded that, in individuals with haplotypes of risk of tau, a partial deficit of parkin function could favor the development of tau pathology. More recently, Yang et al. (20) have found that parkin is essential for the stabilization of tubulin in microtubules. The absence of parkin could, therefore, make unstable the binding of tau to tubulin and increase the levels of tau in the neuronal cytosol, making tau more susceptible to phosphorylation.
In order to test whether the interaction of tau and parkin is relevant in patients with neurodegenerative diseases, we have investigated a mouse model of tauopathy that over-expresses tau and has null parkin function produced by a deletion of exon 3 for parkin. The parkin null animals do not have a deficit of monoamines in basal ganglia (21) but rather increased striatal levels and increased intracellular monoamino oxidase (MAO)-mediated metabolism of dopamine. The enhanced production of free radical via MAO did not produce a massive loss of nigrostriatal dopamine neurons because it was compensated by increased levels of glutathione (GSH). Mice over-expressing mutated tau have also been reported (22, 23) . Mutated tau is hyperphosphorylated, as phosphatase PP2A is unable to bind to it (24) . Mice over-expressing mutated tau appear to behave normally though they have lysosomal abnormalities and hyperphosphorylated tau, but no obvious cellular damage. As both parkin and tau are proteins that play important roles in parkinsonism, we have investigated the effect of combining over-expression of tau with suppression of parkin on: (i) nigrostriatal dopamine and other monoamine neurons, anterior horn cells of the spinal cord; (ii) the homeostasis of important free radical chelating agents such as glutathione; (iii) the expression of glial antigens; and (iv) the expression of proapoptotic, heat shock proteins, c-terminal Hsc interacting protein (CHIP) and GSK-3. Also, we have tested the effect of the absence of parkin on tau pathology. We have found that the animals with mutations of both parkin and tau have histological and biochemical deficits that were not present in any of the groups with homozygous mutations of either gene, further supporting the concept of a functional interaction between tau and parkin.
RESULTS

Breeding, development and behavior
Breeding of the animals was performed according to the following schema. The numbers in brackets represent the expected/found frequencies of genotypes of the offspring expressed in percentage.
Parkin null mice. All the animals used in these experiments were homozygote. For simplicity, mice expressing human-mutated tau are indicated as tau VLW . The four groups of animals developed normally. Therefore, we confirm normal development and growth of parkin-null mutant (parkin 2/2 ) and human-mutated tau over-expressing mice (tau VLW ), as previously reported (21, 23) , the double mutated mice (parkin 2/2 þtau VLW ) weighed less than the mice of the same age from other experimental groups. No abnormal behavior was observed in any of the experimental groups though some double mutant mice dragged their hindlimbs at the end of the observation period.
Motor activity was slightly reduced in tau VLW and in parkin 2/2 þtau VLW mice but the differences were not statistically significant for any of the parameters evaluated in animals from 3 to 5 months (data not shown).
Footprints, as and index of the length of the stride, are presented (Fig. 1) . Double mutant parkin 2/2 þtau VLW mice of 3 and 8 months of age had shorter steps and the abnormality progressively increases with age.
Macroscopic and histologic appearance of the nervous system
The brain and spinal cord appeared macroscopically normal in the four experimental groups and no evidence of cortical atrophy was observed. The findings in hippocampus have been described elsewhere (25) . Essentially, the cellular structure was normal but there were changes in the cellular localization of tau in neurons of the CA1 area in the double parkin 2/2 þtau VLW mice. No immunoreactivity to human tau was observed in wild-type (WT) and parkin 2/2 mice, as expected. There was normal axonal tau immunoreactivity in tau VLW mice, but the immunostaining against human tau was perinuclear in parkin 2/2 þtau VLW mice. Here, we also confirm perinuclear localization of tau in anterior horn cells of the spinal cord (Fig. 2C ) of the double parkin 2/2 þtau VLW mice, but not in other experimental groups. The number of motor neurons was significantly reduced in double mutant mice to 60% of the other experimental groups ( Fig. 2A and B ). Both parkin 2/2 and tau VLW mice had normal appearance of the substantia nigra and normal levels of tyrosine hydroxylase (TH) neurons in their brain stem (Fig. 3) . Mice with mutations of the two genes had a reduction of the area of the substantia nigra and around 50% depletion of TH þ neurons (Fig. 3 ).
Monoamines and their metabolites in double transgenic parkin 2/2 1tau VLW mice
Striatum As previously reported, parkin 2/2 mice do not show reduced dopamine levels in striatum (Fig. 4 ), but they have high levels of monoamine metabolites including MAO-derived metabolites such as di-hydroxyphenyl acetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxy-indole acetic acid (5-HIAA). Tau over-expressing mice, whose levels of monoamines have not been previously reported, had striatal levels of dopamine similar to those of the WT and slightly elevated levels of metabolites, though not as much as in parkin No changes were found in noradrenaline (NA) levels in any of the experimental groups. With regards to serotonin (5-HT) the levels were similar in all groups. The levels of the MAOmediated 5-HT metabolite, 5-HIAA were high in all experimental groups and significant differences were observed in the parkin 2/2 þtau VLW and in parkin 2/2 mice (Fig. 4) .
Limbic system The changes observed in the limbic system (Table 1) were different from that observed in the striatum. Dopamine levels were significantly increased in parkin 2/2 þtau VLW and parkin 2/2 mice and dopamine metabolites were increased in the three experimental groups. The levels of NA, which in the WT controls are around twice the levels found in the striatum, were unchanged in parkin 2/2 mice and in tau VLW mice, but were elevated in parkin 2/2 þtau VLW mice. 5-HT levels were unchanged in the three groups of transgenic animals but 5-HIAA was increased in parkin 2/2 mice and in parkin 2/2 þtau VLW mice.
Diencephalon and brain stem No significant differences in the levels of monoamines and metabolites were found in any of these areas (data not shown).
Protein markers of dopamine neurons
Protein markers of dopamine neurons in striatum are presented in Figure 5 . Parkin 2/2 þtau VLW mice had a reduction of both TH and dopamine transporter (DAT), confirming the abnormalities of nigrostriatal dopamine neurons. No significant changes of these markers were found in any other groups. The density of dopaminergic terminals in striatum, as shown by immunohistochemical staining against TH is presented in Figure 5A .
Glial and neuronal markers in parkin
2/2 1tau VLW striatum Glial and neuronal markers are presented in Figure 6 . GFAP is reduced in parkin 2/2 þtau VLW mice but is not in the other groups. GLUT-5, a marker of resting and reactive microglia, was increased with respect to WT in two groups of mice, parkin 2/2 , and tau VLW . Neuronal enolase is unchanged. Our data suggest a reduction of astrocytes in striatum of parkin 2/ 2 þtau VLW mice without changes of this cellular population in other transgenic animals.
Alteration of GSH homeostasis in parkin
2/2 1tau VLW mice Parkin 2/2 mice have high levels of GSH in striatum (21). Here we confirm ( Fig. 7 ) that finding. We have also observed that tau VLW mice and parkin 2/2 þtau VLW mice have striatal levels of GSH similar to WT. Parkin 2/2 þtau VLW mice had reduced levels of GSH with respect to parkin 2/2 mice. Oxidized glutathione (GSSG) was highest in tau VLW mice. Parkin 2/2 þtau VLW mice had striatal levels of GSSG similar to those of WT but reduced with respect to tau VLW mice. The ratios of GSH/GSSG, which indicate indirectly the reserve of free radical scavengers, were highest in parkin In the limbic system, where the metabolism of dopamine, as measured by the ratio DOPAC/DA, is lower than in the striatum, the levels of GSH, GSSG and GSH/GSSG were unchanged. No difference of these parameters was found in brain stem or diencephalon.
Expression of tau in striatum
Levels of tau, as measured by immunoreactivity to 7.51 antibody, which labels both endogenous mouse tau þ human-mutated tau, were reduced in parkin 2/2 mice with respect to WT. As expected, immunoreactivity to 7.51 antibody was increased, with respect to WT in tau VLW and parkin 2/2 þtau VLW mice, but there was no difference between these two groups ( Fig. 8 ). T14 immunoreactive tau, which labels human mutated tau, was only detected in tau VLW and parkin 2/2 þtau VLW mice and, similarly to 7.51, there was no difference between these two experimental groups.
Expression of heat shock and cell death proteins
Heat shock protein Hsp-70 was increased in parkin 2/2 and, furthermore, in tau VLW mice (Fig. 9 ), but not in parkin 2/2 þtau VLW . As heat shock proteins are non-selective reactants of stress it is conceivable that both parkin 2/2 and tau VLW express neuroprotective proteins in response to the molecular challenges produced by the mutations but parkin 2/2 þtau VLW mice lack that protective mechanism. This is further confirmed by our findings that CHIP/Hsc70, a complex that ubiquitinates phosphorylated tau and enhances cell survival (26) , is significantly reduced in parkin 2/2 þtau VLW mice without significant changes in the other experimental groups. In agreement with this hypothesis, the ratio Bcl-2/Bax, an index of anti-/pro-apoptotic proteins, was reduced in parkin 2/2 and tau VLW mice and, furthermore, in double transgenic.
Expression of GSK-3b and P-Ser GSK-3b
The levels of GSK-3b were increased in parkin 2/2 mice but not in any of the other experimental groups (Fig. 10) . The ratio of inactivated P-Ser9 to total GSK-3b was reduced in parkin 2/2 and parkin 2/2 þtau VLW mice (Fig. 10) suggesting a relative increase of activity-enhanced GSK-3.
DISCUSSION
We have investigated the role of suppressing parkin and over-expressing mutated human tau in mice with single and combined mutations of these Park-2 and Tau genes. We have observed that young adult double mutant mice have evidence for nigrostriatal cell damage including a reduction of TH þ neurons in the substantia nigra, dopamine levels and dopamine cell markers in striatum, as well as a reduction in the expression of astroglial markers. These double mutant mice, in addition, have motor neuron loss.
The phenotypic diversity of clinical signs and symptoms observed in humans with mutations of tau includes dementia, parkinsonism and motor neuron disease. Cognitive deficits have not been observed in these animals though they have histological changes, mostly consistent with nuclear immunoreactivity to tau, in hippocampus (25) . Similarly, no evidence of clear motor deficits (amyotrophy or paraplegia) is observed in 3-month-old animals, in spite of histological and biochemical evidence of severe nigrostriatal damage. It is of interest to take into consideration that patients with parkinsonism do have a long phase of presymtomatic nigrostriatal dysfunction and that motor signs are only detected when there is a massive dropout of nigrostrial dopamine cells, usually greater than 50%. Otherwise our findings are consistent with the spectrum of deficits observed in patients with mutations of tau. It is important to notice that the phenotype of tauopathy was not present in mice with tau mutations and normal parkin function, suggesting that parkin plays a very important role in modulating the toxic role of tau. The abnormalities of gait, as measured by footprint analysis, appear in early adulthood and increased with age in the double transgenic mice, at least up to 8 months of age. We have investigated the mechanisms of cell death in parkin 2/2 þtau VLW mice. Proteins involved in apoptosis were shifted towards cell death in both parkin 2/2 and tau VLW mice and, furthermore, in parkin 2/2 þtau VLW mice. Hsp-70, which is neuroprotective, was increased in both groups of mice with mutations of one gene but not in the group with the mutation of both genes. The complex CHIPHsc70, which attenuates tau aggregation (27) and increases ubiquitination of phosphorylated tau (26) , was reduced in the double transgenic group. The ratio pSer9 to total GSK-3 levels was reduced in parkin 2/2 and parkin 2/2 þtau VLW mice suggesting an excess of activity enhanced GSK-3 in parkin 2/2 þtau VLW mice, which could be responsible, at least in part, for the hyperphosphorylation of tau observed in these animals. GSH was increased in parkin 2/2 , but not in any of the other groups of animals, and with respect to WT, GSSG was increased in tau VLW mice but not in the other groups. Our data suggest that parkin 2/2 and tau VLW mice have dopaminergic nigrostriatal stress that they are able to compensate by different mechanisms. However, the combined effect of the lack of parkin and over-expression of human tau, with three mutations known to produce pathology, damages the nigrostriatal dopamine neurons even in young animals of 3-months of age.
We have found a pronounced effect of the double mutation in nigrostriatal dopamine neurons, demonstrated by the reduction of striatal levels of dopamine and its metabolite DOPAC in these animals as well as by the decrease of the expression of dopamine markers such as TH and DAT proteins. No significant reductions of the levels of dopamine and its metabolites in other brain regions of the double mutant or in any brain area of the single mutant, parkin 2/2 or tau VLW , was observed. In fact the levels of dopamine and its metabolites are increased in parkin 2/2 mice, as previously reported (27) , and confirmed here. The explanation for this selective toxicity is probably related to the different turnover of dopamine in the different dopamine systems. For instance, the ratio DOPAC/DA, which could be considered an indirect index of dopamine turnover, is 0.4 in striatum and 0.06 in the limbic system in our animals. As the conversion of dopamine to DOPAC produces free radicals, one molecule of H 2 O 2 per molecule of dopamine, our data indicates that the special vulnerability of the nigrostriatal system may be related to its enhanced metabolism of dopamine and its excessive production of free radicals, as both parameters are almost 7-fold those of the limbic system. We have previously suggested that high levels of DOPAC in parkin 2/2 mice indicate an accelerated metabolism of dopamine via mono-amino oxidase. High MAO B activity in parkin 2/2 has been recently confirmed (28, 29) . Enhanced MAO-related dopamine metabolism could be compensated by levels of GSH as it is found in parkin 2/2 mice. Direct measurement of sprouting of dopamine nerve terminals is beyond the scope of this study, but there is a discrepancy between cellular changes observed in the substantia nigra and those found in striatum. We support the hypothesis that there should be sprouting. Sprouting of nigrostriatal dopamine terminals have been postulated in patients with Parkinson's disease and in animal models of this disease as an explanation to the relatively mild clinical deficits observed after severe nigral lesions. Parkin 2/2 þtau VLW mice, lacking the high protective levels of GSH found in parkin 2/2 mice, are not protected against the abnormal dopamine metabolism related to the suppression of the parkin function. Therefore, their nigrostriatal dopamine neurons may be damaged and, eventually, disappear. We do not know why this effect is restricted, in animals of 3 months, to the nigrostriatal dopamine neurons and not to other dopamine, noradrenaline or 5-HT neurons in the brain, but it is important to realize that the turnover of dopamine in the nigrostriatal neurons, as measured by the ratio DOPAC/DA, is much greater in the nigrostriatal dopamine neurons than in other monoamine systems in the brain. Furthermore, other parameters, such as high levels of Fe 2þ and low levels of GSH, make the nigrostriatal dopamine system more susceptible.
In addition to the inability to compensate for oxidative stress, other mechanisms appear to be involved in cell death in parkin 2/2 þtau VLW mice. These mechanisms may be related to the shift of anti-/pro-apoptotic proteins, to the reduced expression of Hsp-70 and to the changes in cellular distribution of tau. Nuclear and perinuclear localization of tau has been reported in patients with autosomal dominant frontotemporal dementia with parkinsonism related to the P301L mutation of tau (30) . Elyaman et al. (31) have suggested that there is a link between apoptosis, nuclear translocation of GSK-3 and levels of hyperphosphorylated tau. Lefebvre et al. (32) found that nuclear localization of tau was regulated by the balance of glycosylation and phosphorylation of this protein. Recent studies suggested that the levels of hyperphosphorylated tau modulate nuclear functions such as the expression of the estrogen receptor-alpha in hippocampal neurons of patients with Alzheimer's disease (33) .
The interactions between parkin and tau may be interesting in the pathogenesis of neurodegenerative disorders. Tau pathology is present in the brain of patients with autosomal recessive parkinsonism related to mutations of the gene Park-2 (17) and it has been suggested that tau accumulation in the brains of these patients is related to the fact that parkin is a protein with ubiquitine ligase function and that tau is a substrate of parkin. More recently, parkin has been described as a protein that stabilizes the microtubules (20) . By doing so, it helps the binding of tau to the microtubular transport system, which is critical for neuronal survival and function. In the absence of parkin, the binding of tau to microtubules may be impaired and its cellular distribution and function may change. Guerrero et al. (25) have found abnormal distribution of tau immunoreactivity in hippocampal neurons of parkin 2/2 þtau VLW mice. In these animals tau is localized around the nucleus, instead of its normal distribution in the axon. We have also here observed that tau appears in the nucleus and perinuclear area of motor neurons of the spinal cord. Inability of tau to bind to microtubules may produce two deleterious effects: (i) impairment of the function of the transport system, of critical importance for cell survival and Figure 7 . GSH homeostasis in striatum of WT, parkin 2/2 , tau VLW and parkin 2/2 þtau VLW mice. The GSH and GSSG levels were measured in homogenates of brain regions from 3-month-old male mice. Values are expressed as the mean + SEM (n ¼ 6 animals in each experimental group). Statistical analysis was performed by one-way ANOVA followed by Newman-Keuls test.
Ã P , 0. function, and (ii) increased levels of free cytosolic tau, more susceptible to phosphorylation by kinases. When the levels of phosphorylated tau increase, the self aggregation of tau is enhanced. We would like to hypothesize, according to our data, that in neurons from WT animals, tau phosphorylated by GSK-3 is ubiquitinated by the help of CHIP/Hsc70 and further processed in the proteasome. In neurons from parkin 2/2 þtau VLW , however, the combined effect of enhanced GSK3 activity and the reduction of CHIP increases the levels of nuclear tau, less susceptible to proteosomal degradation.
The interaction between parkin and tau may be clinically relevant. We have created these double transgenic mice to investigate the putative potentiation of toxic effects of mutations of these two genes because we have observed one patient with a single C212Y mutation of parkin, and with the H1/H1 haplotype of tau, who developed a neurological disorder that fulfilled clinical and pathological criteria for PSP (18) . This patient had abnormal tau deposits in midbrain, diencephalon, cortex and other areas of his nervous system and high levels of phosphorylated tau. Heterozygotes for parkin mutations and carriers of the H1 haplotype are usually asymptomatic. It was possible, therefore, that the disease was unrelated to the mutations but it could not be excluded that it was triggered by an interaction of both proteins. It is already known that carriers of H1/H1 genotype have a greater risk of sporadic PSP, which is extremely rare in subjects with H2 haplotype (34) . More recently (35) we have found that the polymorphism VAL380LEU of parkin is more frequent in patients with PSP, suggesting that the presence of Leu in such a position has a neuroprotective effect. This further suggest that the risk of a tauopathy, even in sporadic cases, may be determined by genetic factors, including polymorphisms of parkin. Our data suggest that the mechanism of the disease in individuals with apparently sporadic disorders could be related to the effects of mutations of multiple genes, transmitted with Mendelian inheritance, but insufficient to produce a clinical phenotype in the absence of additional mutations or the coexistence of environmental factors. If this proves to be the case, the identification of genetic risks factors, and not only of mutations, may be critical for the investigation and treatment of disease.
Several studies are under way to experimentally modify the phosphorylation and self-aggregation of tau with promising results in vitro (15, 36) . If these treatments prove helpful, they should be administered to patients with initial clinical syndromes since neuroprotection, even with the best possible treatment, may be useless in patients with fully established disease, in whom there is already massive neuronal loss and tissue degeneration of certain neuronal areas at the time the diagnosis is made. We hope that our study helps to identify factors of risk of tauopathies in patients and to provide a useful model for testing putative treatments of tau-related disorders.
MATERIALS AND METHODS
Transgenic animals
WT C57BL6/129SV and parkin-null mutant (parkin 2/2 ) littermates mice were obtained from Aventis Pharma SA laboratory (Vitry-sur-Seine, France) (21). Human-mutated tau overexpressing mice (tau VLW ) were obtained from Dr J. Avila. The tau VLW line over-expresses a human four-repeat tau isoform with two N-terminal exons carrying three mutations (G272V, P301L and R406W) linked to frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). The mice were generated by pronuclear injection of tau VLW gene driven by the mouse Thy-promoter. All transgenic tau VLW mice used in the experiments described here were homozygotes and the insertion was corroborated using TT1 and TT2 primers to amplify a 470-bp product specifically from the transgene and not from endogenous murine DNA, whereas as an internal control for DNA, TT1 and THY were used to amplify a 450-bp product specifically from murine genomic DNA but not from the transgene (23) . The double mutant parkin 2/ 2 þtau VLW was obtained by breeding the two previously described transgenic mice. Our experiments were performed on littermates generated by a heterozygote intercross. The animals, therefore, have the same genetic background. The confirmation of the genotype in each mouse was performed by standard PCR techniques of genomic DNA obtained from their tail.
Procedures using laboratory animals were in accordance with the European Union Directives. All efforts were made to minimize the number of animals used and their suffering. Twenty-four 3-month-old male mice, divided into four experimental groups of six WT animals, homozygote parkin null (parkin 2/2 ), over-expressing human-mutated tau (tau VLW ) and the double mutant (parkin 2/2 þtau VLW ) were used for biochemical and behavior, and three additional animals of each group for histological studies. Six additional animals per group were used for longitudinal evaluation of motor behavior aged 5 and 8 months.
Motor assessment
Young adult male mice (3 -5-month-old) were used for evaluation of motor activity in open field observation and by computerized analysis of movements in an actimeter (Actitrack, Panlab, Barcelona, Spain). This consisted of a box of 45 Â 45 cm of area, with infra-red beams all around, spaced 2.5 cm, coupled to a computerized control unit. We have analyzed the following parameters: (i) distance run in the actimeter (ambulation); (ii) time spent in slow movements (speed ,5 cm/s); (iii) resting time (inactivity); and (iv) number of head entries into square holes (exploratory activity). The analysis of motor activity was done for periods of 10 min. The experimental set-up used to study the footprint patterns by the mice walking on the 60 cm paper sheet is shown in Figure 1A .
Brain regions and tissue preparation
After decapitation, brain parts used for biochemical studies were dissected, according to Carlsson and Lindqvist (37) and the areas that contain a rich density of dopamine terminals, limbic system and striatum, or DA cell bodies (midbrain) were used for further analysis. The brain parts were frozen on dry ice. Spinal cords were dissected out, immersed in 4% paraformaldehyde for 24 h and used for histological studies. The different brain regions were sonicated (VibraCell, level 2 for 30 s) in eight volumes (w/v) of 0.4 N perchloric acid with 0.5 mM Na 2 S 2 O 5 and 2% EDTA and then centrifuged at 13 400 g for 20 min at 48C. The supernatant was used for monoamines and their metabolites as well as for glutathione determination. The pellet, with the proteins, was neutralized (w/v ¼ 1/9) with the lysis buffer (0.75% Na 2 CO 3 , 2% SDS, 0.25 mM PMSF, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 10 mg/ml pepsin) and then sonicated and centrifuged at 13 400 g for 30 min at 48C. The supernatant was used for protein determination by BCA assay and for electrophoresis analysis.
Histological studies
The animals used for these studies were anesthetized intraperitoneally with a mixture (5:4:1) of ketamine (50 mg/ml), diazepam (1 mg/ml) and atropine (1 mg/ml), and perfused with 4% paraformaldehyde. The whole brain and the spinal cord were immersed in paraformaldehyde for 24 h and then included in paraffin, sectioned in the microtome at a thickness of 4 mm, and stained for haematoxylin/eosine (H&E), Nissl's stain, solocrom for myelin, tyrosine hydroxylase (TH) and tau (AT100) immunoreactivity. Rabbit polyclonal anti TH antibody, from Chemicon, (Madrid, Spain) was diluted 1:2000 and human monoclonal anti PHF tau antibody from Pierce Endogen (Rockford, IL, USA) was diluted 1:100. Anti-mouse and anti-rabbit secondary antibodies were from Dako (Denmark).
The number of TH immunoreactive neurons in the substantia nigra was counted in an Olympus B Â 51 microscope using Cast Grid software. Dopamine cells were quantified stereologically in three regularly spaced sections covering the entire surface of the anterio-posterior extent of the substantia nigra. Similarly, the number of anterior horn cells of the spinal cord were counted in Nissl-stained sections. Motoneurons were quantified stereologically on three regularly spaced sections covering the ventral horn of the lumbar extent of the spinal cord. Figure 10 . Striatal levels of GSK-3b, P-Ser-GSK-3b and P-Ser-GSK-3b/GSK-3b of WT, parkin 2/2 , tau VLW , and parkin 2/2 þtau VLW mice. Representative western blots of GSK-3b (A), P-Ser GSK-3b (B) proteins and P-Ser GSK-3b/GSK-3b (C) are presented. b-actin was used as charge control. Values are expressed as the mean + SEM (n ¼ 6 animals in each experimental group). Statistical analysis was performed by one-way ANOVA followed by NewmanKeuls test.
Ã P , 0.05, ÃÃ P , 0.01 transgenic mice versus WT mice.
Determination of monoamines and their metabolites
The brain regions were frozen on dry ice and the levels of DA and its metabolites, 3-methoxy-tyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), noradrenaline (NA) and its metabolite, 4-hydroxy-3-methoxy-phenyl-glycol (MHPG), serotonin (5-HT) and its metabolite, 5-hydroxy-indole-acetic acid (5-HIAA), were measured by HPLC with an ESA coulochem detector, according to Mena et al. (38) . Briefly, the tissue was sonicated in 8 vol (w/v) of 0.4 N perchloric acid (PCA) with 0.5 mM Na 2 S 2 O 5 and 2% EDTA and then centrifuged for 10 min. Monoamine levels were determined from 20 ml of the resulting supernatant. The chromatographic conditions were: a column Nucleosil 5C18; the mobile phase, a citrate/acetate buffer 0.1 M, pH 3.9 with 10% methanol, 1 mM EDTA and 1.2 mM heptane sulfonic acid; and the detector voltage conditions: D1 (þ0.05), D2 (20.39 ) and the guard cell (þ0.40).
Glutathione measurements
Total glutathione (GSx) levels were measured by the method of Tietze (39) . A sample (40 ml) of the homogenated brain regions supernatant in 0.4 N PCA was neutralized with four volumes of phosphate buffer (0.2 M NaH 2 PO 4 , 0.2 M Na 2 HPO 4 , 0.5 M EDTA, and pH 7.5). Fifty microlitres of the resulting preparation were mixed with DTNB (0.6 mM), NADPH (0.2 mM) and glutathione reductase (1 unit) and the reaction was monitored in a P96 automatic microtiter reader at 412 nm for 6 min. Oxidized glutathione (GSSG) was measured by the method of Griffith (40) . After the neutralization with the phosphate buffer, the sample remaining (120 ml) was mixed with 2-vinylpyridine (1.2 ml) at room temperature for 1 h and the reaction was carried out as described earlier. Reduced glutathione (GSH) was obtained by subtracting GSSG levels from GSx levels.
Western blot
Samples (20-50 mg) were added to SDS sample loading buffer 2X (10% glycerol, 2% SDS, 0.1% bromophenol blue, 50 mM Tris, pH 6.8 and 5% b-mercaptoethanol), electrophoresed in 10% SDS-polyacrylamide gels and then electroblotted to 0.45 mM nitrocellulose membranes. For immunolabeling, the blots were blocked with TTBS solution (20 mM Tris-HCl, pH 7.6, 137 mM NaCl plus 0.1% Tween 20) and 5% dry skimmed milk, for 1 h at room temperature. After blocking non-specific binding, the membranes were incubated overnight with specific antibodies in blocking solution at 48C.
Later, blots were washed twice with blocking solution for 10 min followed by another two washes with TTBS for 5 min each. The blots were developed by chemiluminescence detection using a commercial kit (ECL-Amersham Biosciences) and quantified by computer-assisted video densitometry. b-actin was used as a control of charge.
Antibodies
Mouse monoclonal anti-glial fibrillar acid protein (GFAP) antibody diluted 1:5000, mouse monoclonal anti-tyrosine hydroxylase (TH) antibody (1:5000) and rat monoclonal antidopamine transporter (DAT) (1:2500) were from Chemicon; mouse monoclonal anti-Bcl2 (1:500), rabbit polyclonal anti-Bax (1:750) and mouse monoclonal anti Hsp-70 (1:100) were from Santa Cruz; rabbit polyclonal anti-b-tubulin (1:10 000) was from Covance; rabbit polyclonal anti-human GLUT-5 (1:250) was from IBL-Hamburg; rabbit anti-rat neuron specific enolase (NSE) (1:1000) was from Polysciences; mouse monoclonal anti-CHIP (1:1000) was from Abcam; rabbit polyclonal anti-phospho GSK 3a/b (21/9) (1:1000) was from Cell Signaling; mouse monoclonal anti GSK 3a/b (1:1000) was from BD Biosciences; mouse monoclonal anti-human tau T14 (1:1000) was from Zymed; mouse monoclonal anti-tau 7.51 (1:1000) was a generous gift from Dr Avila; mouse monoclonal anti-b-actin antibody diluted 1:5000 was from Sigma.
Anti-mouse and anti-rabbit secondary antibodies diluted 1:1000 were from Amersham. b-actin secondary antibody was an anti-mouse phosphatase alkaline conjugate diluted 1:3000 from Sigma.
Antibodies used for immunohistochemistry were the following: rabbit anti-tyrosine hydroxylase polyclonal antibody from Chemicon, diluted 1:500 and anti-human PHF-tau monoclonal antibody (AT100) from Pierce Endogen, Rockford, IL, USA, diluted 1:500.
Statistical analysis
The results were statistically evaluated with different tests. Significant differences between the four experimental groups were analyzed with one and two way analysis of variance (ANOVA) followed by the Newman -Keuls multiple comparison test or Bonferroni test, respectively, as a post hoc evaluation. Differences were considered statistically significant when P , 0.05.
